Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Intervalo de año de publicación
1.
Retin Cases Brief Rep ; 9(1): 61-3, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25383852

RESUMEN

PURPOSE: Mutations in the MFRP (membrane-type frizzled-related protein) gene leads to an entity characterized by retinitis pigmentosa, nanophthalmos, optic disk drusen, and macular changes, originally described as foveoschisis. Despite the association of MFRP gene mutation and increase in macular thickness, no treatment modality has been described for cystoid macular edema related to this particular entity so far. METHODS: In this case report, a 52-year-old woman presented with nanophthalmos, optic disk drusen, retinitis pigmentosa, and increase in macular thickness. Genetic analysis revealed an MFRP gene mutation. The patient was treated with topical carbonic anhydrase inhibitors. RESULTS: A progressive decrease in macular thickness and cystic changes was observed during the 2-month course of topical carbonic anhydrase inhibitor treatment, and best-corrected visual acuity improved from 20/100 to 20/50. Macular thickness remained stable after 6 months of follow-up. CONCLUSION: Cystoid macular edema is part of the macular changes noted in the MFRP mutation-related nanophthalmos-retinitis pigmentosa-foveoschisis-optic disk drusen, syndrome. Taking into account that resolution of cystoid macular edema in patients with retinitis pigmentosa may delay an irreversible decrease in visual acuity, treatment should be considered when cystic changes are suspected. Topical carbonic anhydrase inhibitor was effective in decreasing macular thickness and cystic changes in the patient reported.


Asunto(s)
Inhibidores de Anhidrasa Carbónica/administración & dosificación , Proteínas de la Membrana/genética , Microftalmía/tratamiento farmacológico , Drusas del Disco Óptico/tratamiento farmacológico , Retinitis Pigmentosa/tratamiento farmacológico , Sulfonamidas/administración & dosificación , Tiofenos/administración & dosificación , Administración Tópica , Femenino , Mutación del Sistema de Lectura , Humanos , Edema Macular/tratamiento farmacológico , Persona de Mediana Edad , Síndrome , Resultado del Tratamiento
2.
Biull Eksp Biol Med ; 79(4): 110-2, 1975 Apr.
Artículo en Ruso | MEDLINE | ID: mdl-1191756

RESUMEN

In mice, homozygous by microphthalmia (mi/mi) gene the disturbance of dental development was due to defects in dental pulp and to the absence of bone resorpion. Administration of heparin or parathyroid hormone stimulated dental eruption in mi/mi mice. Following combined action of heparin and parathyroid hormone the number of erupted teeth was practically the same as after the action of heparin alone. Possibly the level of heparin is insufficient, but secretion of parathyroid hormone is unimpaired in mi/mi mice.


Asunto(s)
Heparina/farmacología , Microftalmía/genética , Hormona Paratiroidea/farmacología , Erupción Dental/efectos de los fármacos , Animales , Ratones , Microftalmía/tratamiento farmacológico , Odontogénesis/efectos de los fármacos , Anomalías Dentarias/etiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA